Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

• Published in: European journal of neurology Vol. 25; no. 3; pp. 527 - 534
• Main Authors: Olberg, H. K., Eide, G. E., Cox, R. J., Jul‐Larsen, Å., Lartey, S. L., Vedeler, C. A., Myhr, K.‐M.
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.03.2018
• Subjects: Adult; Antibodies, Viral - blood; Antibody response; Copolymer 1; Female; Fingolimod Hydrochloride - pharmacology; Glatiramer Acetate - pharmacology; Hemagglutination inhibition; Humans; Immunization; Immunogenicity, Vaccine - immunology; Immunologic Factors - pharmacology; Immunomodulation; Immunomodulators; immunotherapy; Influenza; Influenza Vaccines - immunology; Interferon; Interferon beta-1b - pharmacology; Male; Middle Aged; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Natalizumab - pharmacology; Patients; protection; seasonal influenza vaccination; Seasons; Therapy; Vaccination; Vaccines; Viruses; seasonal influenza vaccination; immunomodulation; protection; multiple sclerosis; immunotherapy
• ISSN: 1351-5101; 1468-1331; 1468-1331
• DOI: 10.1111/ene.13537

Background and purpose We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further investigate the influence of immunomodulatory therapies on the antibody resp...